retatrutide phase 2 results obesity nejm 2023 Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks Retatrutide Week by Week: Weight

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Can Retatrutide Dosing Be Reduced Due to Side Effects

Retatrutide Complete Hub Everything about the triple agonist in one place.

took a leap of faith and paid for it

This three-pronged approach is what separates it from every other compound on the market or in development

Theres nothing more fun than having my kids come and watch me play pickleball and say, Mommy, you hit that ball really good. Theyre seeing a strong role model, she says